Clinical Trial

Antegrade Intestinal Fluid Reinfusion for Prevention of Low Anterior Resection Syndrome After Low Anterior Resection: a Single-Center, Prospective Randomized Controlled Trial.

Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to learn if antegrade intestinal fluid reinfusion works to prevent low anterior resection syndrome (LARS) in patients with prophylactic ileal stoma. The main questions it aims to answer are: 1. Does it work to prevent LARS by antegrade intestinal fluid reinfusion before performing the ileostomy reversal surgery? 2. Is antegrade intestinal fluid reinfusion more effective than water infusion in preventing LARS. Participants will: 1. Receive either antegrade intestinal fluid reinfusion or antegrade water infusion through ileal stoma based on the standard of care at 1 month after anterior rectal resection, until the ileostomy reversal. 2. Keep a diary of their symptoms.
Trial Details
NCT Number NCT07537998
Lead Sponsor Pei-Rong Ding
Conditions Low Anterior Resection Syndrome, Rectal Cancer
Enrollment 160 participants
Start Date 2026-04-10
Primary Completion 2027-04-10 (estimated)
Study Completion 2028-04-10 (estimated)
Updated on ClinicalTrials.gov 2026-04-17